Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 4, 2000, Pages 949-956

  Rossi, Gian Paolo ^a,c   Sacchetto, Alfredo ^a   Rizzoni, Damiano ^b   Bova, Sergio ^a   Porteri, Enzo ^b   Mazzocchi, Giuseppina ^a   Belloni, Anna S ^a   Bahcelioglu, Meltem ^a   Nussdorfer, Gastone G ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiotensin; Endothelin; Hypertension; Receptor antagonists; Target organ damage

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ENDOTHELIN; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RECEPTOR BLOCKING; RECEPTOR DENSITY; STEROID BLOOD LEVEL; TARGET ORGAN; TRANSGENIC ANIMAL;

EID: 0034035143     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.4.949     Document Type: Article

References (51)

1. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens. 1998;16:1891-1895.
2. Lee ME, Bloch KD, Clifford JA, Quertermous T. Functional analysis of the endothelin-1 gene promoter: evidence for an endothelial cell specific cis-acting sequence. J Biol Chem. 1990;265:10446-10450.
3. Barton M, Shaw S, d'Uscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun. 1997;238:861-865.
4. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999;43:300-307.
5. Hahn AW, Resink TJ, Scott Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1990;1:649-659.
6. Resink TJ, Scott-Burden T, Buhler FR. Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Comm. 1988;157:1360-1368.
7. Sung CP, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther. 1994;271: 429-437.
8. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753-757.
9. Chua BH, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1993;1178:201-206.
10. Ho H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
11. Ishiye M, Umemura K, Uematsu T, Nakashima M. Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin. Eur J Pharmacol. 1995;280:11-17.
12. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435-441.
13. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96: 1593-1597.
14. Moreau P, Takase H, Kung CF, Shaw S, Luscher TF. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension. 1997;29:763-769.
15. Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension. 1995;25: 1191-1195.
16. Balakrishnan SM, Wang HD, Gopalakrishnan V, Wilson TW, McNeill JR. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension. 1996;28:806-809.
17. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension. 1998;31:10-14.
18. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol. 1996;271:H88-H93.
19. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens. 1996;14:57-64.
20. Schricker K, Scholz H, Hamann M, Clozel M, Kramer BK, Kurtz A. Role of endogenous endothelins in the renin system of normal and two-kidney, one clip rats. Hypertension. 1995;25:1025-1029.
21. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, Bauer C. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension. 1999;33:816-822.
22. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A, Harrison DG. Role for endothelin-1 in angiotensin II-raediated hypertension. Hypertension. 1997;30:29-34.
23. Tank JE, Vora JP, Houghton DC, Anderson S. Altered renal vascular responses in the aging rat kidney. Am J Physiol. 1994;266:F942-F948.
24. Weber H, Webb ML, Serafino R, Taylor DS, Moreland S, Norman J, Molloy CJ. Endothelin-1 and angiotensin-II stimulate delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for common signaling mechanisms. Mol Endocrinol. 1994;8:148-158.
25. Hilgers KF, Peters J, Veelken R, Sommer M, Rupprecht G, Ganten D, Luft FC, Mann JF. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension. 1992;19:687-691.
26. Struijker-Boudier HA, van Essen H, Fazzi G, De Mey JG, Qiu HY, Levy BI. Disproportional arterial hypertrophy in hypertensive mRen-2 transgenic rats. Hypertension. 1996;28:779-784.
27. Sander M, Bader M, Djavidani B, Maser Gluth C, Vecsei P, Mullins J, Ganten D, Peters J. The role of the adrenal gland in hypertensive transgenic rat TGR(mREN2)27. Endocrinology. 1992;131:807-814.
28. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ. Endothelin in the kidney in malignant phase hypertension. Hypertension. 1995;26:925-931.
29. Cargnelli G, Rossi GP, Pessina AC, Luciani S, Debetto P, Ganten D, Peters J, Bova S. Changes of blood pressure and aortic strip contractile responses to ET-1 of heterozygous female transgenic rats, TGR(mRen2)27. Pharmcol Res. 1998;37:207-211.
30. Gardiner SM, March JE, Kemp PA, Mullins JJ, Bennett T. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br J Pharmacol. 1995;116:2237-2244.
31. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal, Hirth G, Muller M, Neidhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228-235.
32. Mulvany MJ, Halpern W.. Contractile properties of small resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977;41:19-26.
33. Mulvany MJ, Hansen PK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res. 1978;43:854-864.
34. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti-Rosei E. Delayed development of hypertension after short-term nitrendipine treatment. Hypertension. 1994;24:131-139.
35. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Cinelli A, Agabiti-Rosei E. Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension. 1995;26: 118-123.
36. Kuhar MJ. Receptor localization with microscope. In: Yamamura HI, Enna SJ, Kuhar MJ, eds. Neurotransmitter Receptor Binding. New York, NY: Raven Press; 1985:153-176.
37. Palacios JM, Cortes R, Dietl MM. A laboratory guide for the in vitro labelling of receptors in tissue sections for autoradiography. In: Van Leeuwe FW, Buijs RM, Pool CW, Pach O, eds. Molecular Neuroanatomy. Amsterdam, Netherlands: Elsevier/North Holland; 1988:95-110.
38. Rossi GP, Albertin G, Belloni A, Zanin L, Biasolo MA, Prayer Galetti T, Bader M, Nussdorfer GG, Palù G, Pessina AC. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest. 1994;94:1226-1234.
39. Belloni A, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, Nussdorfer GG. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27:1153-1159.
40. Mazzocchi G, Rossi GP, Neri G, Malendowicz LK, Albertin G, Nussdorfer GG. 11β-Hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. FASEB J. 1998;12:1533-1539.
41. Rebuffat P, Rocco S, Andreis PG, Neri G, Nowak KW, Peters J, Opocher G, Mazzocchi G, Mantero F, Nussdorfer GG. Morphology and function of the adrenal zona glomerulosa of transgenic rats TGR [mREN2] 27: effects of prolonged sodium restriction. J Steroid Biochem Mol Biol. 1995;54:155-162.
42. Strachan FE, Spratt JC, Wilkinson IB, Webb DJ. Systemic blockade of the ETB receptor increases peripheral vascular resistance in healthy volunteers in vivo. Hypertension. 1998;32:618. Abstract.
43. Massart PE, Hodeige DG, Van Mechelen H, Charlier AA, Ketelslegers JM, Heyndrickx GR, Donckier JE. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension. J Hypertens. 1998;16:835-841.
44. Wilkinson-Berka J, Kelly D, Cooper M, Skinner S. Bosentan normalizes blood pressure, but does not prevent renal pathology in the diabetic REN-2 rat. Hypertension. 1998;32:608-608. Abstract.
45. Bachmann J, Feldmer M, Ganten U, Stock G, Ganten D. Sexual dimorphism of blood pressure: possible role of the renin-angiotensin system. J Steroid Biochem Mol Biol. 1991;40:511-515.
46. Cargnelli G, Rossi G, Bova S, Pessina AC. In vitro vascular reactivity to endothelin: a comparison between young and old normotensive and hypertensive rats. Clin Exp Hypertens. 1990;12:1437-1451.
47. Zanin L, Rossi GP, Pauletto P, Tonello M, Cargnelli G, Pessina AC. Decreased density of endothelin-1 binding sites in aortic smooth muscle cells of spontaneously hypertensive rats. J Hypertens. 1991;9(suppl): S190-S191.
48. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev. 1990;70:921-961.
49. Orth SR, Esslinger JP, Amann K, Schwarz U, Raschack M, Ritz E. Nephroprotection of an ET(A)-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension. 1998;31:995-1001.
50. Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, Joles JA. Early-onset but not late-onset endothelin-A receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension. 1999;33: 137-144.
51. Teisman AC, Pinto YM, Buikema H, Flesch M, Bohm M, Paul M, van Gilst WH. Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats. J Hypertens. 1998;16:1759-1765.